Arrowhead Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Arrowhead Pharmaceuticals, Inc. Overview

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them using a broad portfolio of RNA chemistries and efficient modes of delivery. The company received its first FDA regulatory approval in November 2025 and began the next phase of growth as a commercial company marketing its own medicines. With a market capitalization of $9.05 billion, the company operates within the biotechnology industry.

Strategic Profile

The company received regulatory approval for REDEMPLO in familial chylomicronemia syndrome in three different countries and launched its first commercial product in the U.S. Arrowhead received a $200 million upfront payment from Novartis and is eligible to receive development, regulatory, and sales milestone payments of up to $2 billion with tiered royalties on commercial sales up to the low double digits. The company has demonstrated significant revenue growth with a 3-year revenue growth rate of 39%.

Competitive Landscape

Arrowhead is an American biotechnology company focused on developing medicines for diseases with genetic origin, with portfolio targeting cardiovascular, cardiometabolic, central nervous system, pulmonary, liver, muscular, and complement-mediated diseases. The company competes with other RNAi therapeutics developers including Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Wave Life Sciences in the gene-silencing space.

Industry Context

Arrowhead Pharmaceuticals, Inc. operates in Biotechnology / RNA Therapeutics.

Key facts

Founded: 2008 · Headquarters: Pasadena, US · Revenue: $264M (Q1 FY2026) · Market cap: $9.05B